期刊
DIABETOLOGIA
卷 61, 期 10, 页码 2134-2139出版社
SPRINGER
DOI: 10.1007/s00125-018-4678-z
关键词
Diabetes mellitus; Diabetic kidney disease; Heart failure; Non-alcoholic fatty liver disease; Non-diabetic chronic kidney disease; Review
资金
- Sanofi-Genzyme
- Actelion
- Boehringer Ingelheim
Individuals with diabetes mellitus exhibit an increased propensity to develop cardiovascular disorders such as coronary artery disease, stroke and heart failure. Over recent decades, numerous cardiovascular outcome trials in individuals with type 2 diabetes have been published, with data showing a reduction of cardiovascular morbidity and mortality by sodium-glucose cotransporter 2 (SGLT2) inhibitors. These results not only provide novel therapeutic options for this high-risk population but also advance our current understanding of cardiovascular risk reduction in diabetes. The current overview article summarises these aspects and discusses future treatment strategies with SGLT2 inhibitors in diabetic and non-diabetic individuals with chronic kidney disease, liver disease and heart failure.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据